H&amp;uuml;rthle cell carcinoma: current perspectives

Ahmadi, Sara; Stang, Michael T.; Jiang, Xiaoyin Sara; Sosa, Julie Ann

doi:10.2147/ott.s119980

Cited by 60 publications

(55 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oncocytic follicular cells of thyroid, known as Hurthle cells, which were irst described by Karl Hürthle are the origin of Hurthle cell carcinoma (HCC) [70,71]. They can be found in both benign and malignant conditions of thyroid.…”

Section: Hurthle Cell Carcinomamentioning

confidence: 99%

“…Since the preoperative diagnosis of HCC is impossible by cytology, determining the initial extent of surgery and whether further surgical resection (completion thyroidectomy) involves postoperative histological evaluation [70]. So, the irst step is a thyroid lobectomy in the primary surgery unless the pathological features guide us to total thyroidectomy.…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Thyroid Cancers: Considerations, Classifications, and Managements

Khosravi¹,

Kouhi²,

Saeedi³

et al. 2017

Diagnosis and Management of Head and Neck Cancer

View full text Add to dashboard Cite

Rapidly increasing trend of thyroid cancer incidence has turned this disease into a global concern. An estimated number of 64,300 new cases of thyroid cancer occurred in men and women in 2016, which represents 3.8% of all new cancer cases of USA (htps://seer. cancer.gov/statfacts/html/thyro.html). Thus, there is a high possibility for every physician to encounter a case of thyroid cancer during his/her professional lifetime. In this chapter, we clariied epidemiology, diferent categories, and new approaches toward diagnosis and management of thyroid cancer.Keywords: thyroid cancer, epidemiology, diferentiated thyroid cancer, undiferentiated thyroid cancer, thyroid nodule Detailed epidemiology of thyroid cancerAs the most common endocrine cancer and ifth most common cancer in women, thyroid cancer includes approximately 1-1.5% of all new cases of cancer diagnosed annually in the USA based on previous data [1][2][3]. Thyroid cancer is more prevalent among women and those with positive family history of thyroid disease. Some prior studies have reported a worldwide increasing trend for thyroid cancer incidence in recent decades [4]. Annual percent change (APC) is a commonly used indicator for the assessment of changes in incidence. Based on US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program, it has been reported 2.4% from 1980 to 1997 and 6.6% from 1997 to 2009 in both genders for thyroid cancer (data available at htp://seer.cancer.gov/statfacts/html/thyro.html).© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.According to [2009][2010][2011][2012][2013] data, the rate of new cases of thyroid cancer was 13.9 per 100,000 men and women per year (Figure 1). Table 1 summarizes number of new cases per 100,000 persons by race/ethnicity and sex. A recently published study on adolescent cancer incidence during 1975-2012 has reported a 2.12% increase for females and 1.59% for males between 15 and 19 years of age [5]. However, there is a study indicating that thyroid cancer incidence trend has slowed following release of American Thyroid Association (ATA) guideline in 2009 [6, 7]. It has been reported that overall thyroid cancer incidence had an increasing trend about 8% per year from 2000 to 2009. But APC showed a deceleration about 3% in men and 2.8% in women, which was conined to tumors less than 2.9 cm of size for women [7].Also, thyroid cancer-related mortality was estimated to consist 0.3% of all cancer-related deaths in 2016. A 5-year survival rate of 98.1% has been reported for thyroid cancer. Despite increasing trend of incidence, thyroid cancer mortality has a relatively stable rate about 0.5 cases per 100,000 persons both from 1973 to 2002 and 2009 to 2013 [8, 9].In conclusion, it seems that thyroid cancer has been following an ...

show abstract

Section: Hurthle Cell Carcinomamentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

Thyroid Cancers: Considerations, Classifications, and Managements

Khosravi¹,

Kouhi²,

Saeedi³

et al. 2017

Diagnosis and Management of Head and Neck Cancer

View full text Add to dashboard Cite

show abstract

“…La falta de diagnóstico de certeza prequirúrgico puede llevar a un tratamiento subóptimo. El uso de marcadores moleculares en el material de PAAF parece tener limitaciones en el caso del CCH 16 , debido al menor conocimiento de los eventos involucrados en la carcinogénesis de estos tumores. Los eventos tumorogénicos más frecuentes en carcinoma papilar de tiroides (mutaciones de BRAF y rearreglos de RET/PTC) no se refirieron en CCH.…”

Section: Discussionunclassified

Carcinoma de células de Hürthle. Análisis cooperativo de los dos hospitales oncológicos de la Ciudad de Buenos Aires

Adamo¹,

Califano²,

Garayalde³

et al. 2017

Rev Argent Cirug

View full text Add to dashboard Cite

Antecedentes: dada su baja incidencia, diferencia citológica con el CFT, mayor diseminación linfática, escasa avidez por el I131 y menor sobrevida que el CFT, el carcinoma de células de Hürthle (CCH) es una entidad polémica y controvertida. Objetivo: informar la experiencia de dos centros oncológicos en el manejo de pacientes con diagnós-tico histológico de CCH. Material y métodos: el tratamiento quirúrgico preferido fue tiroidectomía total en 89,4%; en el 42% se agregó linfadenectomía laterocervical, II-IV en 6 casos y II-V con resección del músculo esternocleidomastoideo, vena yugular interna y nervio recurrente en 2. En 1 de estos se realizó resección de pared traqueal y traqueostomía. La congelación intraquirúrgica confirmó el diagnóstico en el 23%. El 31,5% de los pacientes no recibió tratamiento ablativo con yodo radiactivo. Resultados: tres pacientes fueron reintervenidos por recurrencias locorregionales. Dos evolucionaron con metástasis (mts) a distancia. En 3 se efectuó radioterapia externa ante enfermedad irresecable y 1 recibió inhibidores de tirosina quinasa. Conclusiones: el manejo de los pacientes con CCH, por su baja frecuencia y falta de evidencia de alta calidad, continúa presentando aspectos controvertidos. Se requieren estudios clínicos multicéntricos que incluyan mayor número de pacientes y prolongado tiempo de seguimiento para evaluar el impacto de las diferentes terapéuticas, así como profundizar en el conocimiento de la biología molecular de esta patología. RESUMEN ABSTRACTBackground: in view of its low incidence, cytological difference with follicular cells carcinoma (FCC), higher lymphatic spread, little 131I avidity and less specific survival than FCC, Hürthle Cells Carcinoma (HCC) is a polemic and controversial issue. Objective: to report experience of two oncologic Hospitals in the management of patients with histologic diagnosis of CCH. Material and methods: treatment of choice was total thyroidectomy in 89.4%. In 42% lateral neck dissection was done, II-IV in 6 patients and II-V in 2 patients with resection esternocleidomatoid muscle, internal yugular vein and recurrent nerve. In 1 of these, resection of tracheal wall and tracheostomy was done. Intraoperative frozen sections confirmed diagnosis in 23%. 31.5% did not received therapeutic ablative dosis of I 131. Results: 3 patients were surgically treated for local regional disease. 2 of them developed distant metastases. 3 received radiotherapy and 1 tirosin kinase inhibitors. Conclusions: given its low incidence and absence of high quality evidence, management of HCC is controversial. Other multicentric trials with more patients and follow up are required for evaluation of different therapies, as well as better study about molecular biology of this pathology.

show abstract

“…RAI administration was associated with a 30% reduction in mortality (hazard ratio = 0.703, P = 0.001), and is advocated for tumors >2 cm or nodal/ distant metastatic disease. The latter view is also shared by Ahmadi et al [62] The NCCN guideline recommends RAI ablation for gross extra-thyroidal extension/primary tumor size >4 cm/ extensive vascular invasion/post-operative unstimulated Tg >5-10 ng/L [59] . RAI ablation can be selectively recommended for primary tumor 2-4 cm/minor vascular invasion/cervical lymph node metastases/post-operative unstimulated Tg <5-10 ng/mL.…”

Section: Updates On Treatment and Outcomementioning

confidence: 99%

“…In the literature, modern series are more important than the older ones, as the diagnosis and treatment of thyroid cancer have changed over the years [9,10] . Older series may consist of lesions that look similar to HCC but are actually other types of thyroid cancers.…”

Section: Updates On Diagnosis and Investigationsmentioning

confidence: 99%

Overview of Hurthle cell carcinoma of thyroid

Korzeniowski

Mahmud

Kirby³

et al. 2017

Adv Mod Oncol Res

View full text Add to dashboard Cite

Abstract:The clinical behaviour of Hurthle cell carcinoma (HCC) of the thyroid is variable and there are many controversies in the literature. Here, we summarize an up-to-date review of the literature on genetics, diagnosis (ultrasound scan, fine needle aspiration, frozen section, etc.), and management. At presentation, treatment decision should be made by a multidisciplinary board. Recurrent HCCs are seldom curable despite salvage treatments, which include radioactive iodine ablation, radiofrequency ablation, ethanol ablation, external radiotherapy, and systemic therapy. Further research is needed to develop more efficacious systemic treatments. Currently, lenvatinib, sunitinib, and sorafenib are available. The completed and ongoing clinical trials for HCC are summarized.

show abstract

Hürthle cell carcinoma: current perspectives

Cited by 60 publications

References 64 publications

Thyroid Cancers: Considerations, Classifications, and Managements

Thyroid Cancers: Considerations, Classifications, and Managements

Carcinoma de células de Hürthle. Análisis cooperativo de los dos hospitales oncológicos de la Ciudad de Buenos Aires

Overview of Hurthle cell carcinoma of thyroid

Contact Info

Product

Resources

About